Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 Side effects  



2.1  Breathing problems  





2.2  Mental health problems  





2.3  Other  







3 Society and culture  



3.1  Legal status  





3.2  Other names  







4 References  














Xywav






Igbo
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Xywav
Combination of
Calcium oxybateCentral nervous system depressant
Magnesium oxybateCentral nervous system depressant
Potassium oxybateCentral nervous system depressant
Sodium oxybateCentral nervous system depressant
Clinical data
Trade namesXywav
Other namesJZP-258
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa621001
License data
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Xywav is a medication used to treat cataplexyorexcessive daytime sleepiness.[2][3] It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate.[2] It is a central nervous system (CNS) depressant and it is taken by mouth.[2]

Manufactured by the Jazz Pharmaceuticals company, it was approved for medical use in the United States in July 2020.[2][4][5]

Medical uses[edit]

Xywav is indicated for the treatment of cataplexy or excessive daytime sleepiness in people aged seven years of age and older with narcolepsy;[2][6] and for idiopathic hypersomnia.[6][7]

Side effects[edit]

The US Food and Drug Administration (FDA) label for Xywav contains a boxed warning for central nervous system depression, abuse, and misuse.[2]

Breathing problems[edit]

Slowed breathing, trouble breathing, sleep apnea.[2]

Mental health problems[edit]

Confusion, hallucination, unusual or disturbing thoughts (abnormal thinking), anxiety, depression, suicidal thoughts or actions, increased tiredness, feelings of guilt or worthlessness, and difficulty concentrating.[2]

Other[edit]

Sleepwalking.[2]

Society and culture[edit]

Legal status[edit]

The sodium oxybate component of Xywav was granted orphan drug designation in November 1994 by the FDA.[8][6] Xywav is a prescription drug and a Schedule III controlled substance in the United States.[2]

Other names[edit]

In the testing phase of the drug, it was known as JZP-258.[9]

Calcium, magnesium, potassium, and sodium oxybate is another name for gamma hydroxybutyrate (GHB).[10][11]

References[edit]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  • ^ a b c d e f g h i j k "Xywav - calcium, magnesium, potassium, and sodium oxybates solution". DailyMed. Archived from the original on 13 August 2021. Retrieved 12 August 2021.
  • ^ Halter MJ, Fratena CA (November 2021). "Sleep-Wake Medications". Varcarolis' Manual of Psychiatric Nursing Care. Elsevier Health Sciences. p. 398. ISBN 978-0-323-79306-3. Archived from the original on 20 June 2022. Retrieved 23 December 2021.
  • ^ "Drug Approval Package: Xywav". U.S. Food and Drug Administration (FDA). 7 May 2021. Archived from the original on 13 August 2021. Retrieved 12 August 2021.
  • ^ "Drug Approval Package: Xywav". U.S. Food and Drug Administration (FDA). 7 May 2021. Archived from the original on 27 December 2021. Retrieved 19 November 2021.
  • ^ a b c "FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment". U.S. Food and Drug Administration (FDA) (Press release). 12 August 2021. Archived from the original on 12 August 2021. Retrieved 12 August 2021.
  • ^ "Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults" (Press release). Jazz Pharmaceuticals. 12 August 2021. Archived from the original on 12 August 2021. Retrieved 12 August 2021 – via PR Newswire.
  • ^ "Xywav Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 13 August 2021. Retrieved 12 August 2021.
  • ^ "Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy". Archived from the original on 20 September 2022. Retrieved 20 September 2022.
  • ^ "Calcium, Magnesium, Potassium, and Sodium Oxybate: MedlinePlus Drug Information". American Society of Health-System Pharmacists. Archived from the original on 6 June 2023. Retrieved 29 December 2023.
  • ^ "F.D.A. Approves GHB, a 'Date Rape' Drug, for Narcolepsy Patients". The New York Times. 12 August 2021. Archived from the original on 13 August 2021. Retrieved 13 August 2021.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Xywav&oldid=1212001443"

    Categories: 
    Drugs not assigned an ATC code
    Narcolepsy
    Organic sodium salts
    Orphan drugs
    Treatment of sleep disorders
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Use American English from August 2021
    All Wikipedia articles written in American English
    Use dmy dates from August 2021
    Drugs with non-standard legal status
    Chemical articles without CAS registry number
    Articles without EBI source
    Chemical pages without ChemSpiderID
    Chemical pages without DrugBank identifier
    Articles without InChI source
    Articles without UNII source
    Articles containing unverified chemical infoboxes
    Drugs that are a combination of chemicals
     



    This page was last edited on 5 March 2024, at 17:49 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki